Prescription Drugs 2 Go

Updated Date: Jul 20, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Authors: Rodriguez-Tudela JL, Gomez-Lopez A, Arendrup MC, Garcia-Effron G, Perlin DS, Lass-Flörl C, Cuenca-Estrella M
According to the product insert for Cancidas, the drug must not be diluted in solutions containing glucose as this decreases caspofungin stability. The aim of this study is to compare caspofungin MICs for a collection of yeasts by means of EUCAST EDef7.1 but using two different concentrations of glucose, 2% versus 0.2%. MICs were identical or within one twofold dilution for 93 out of 95 strains (97.9%) of strains showing that glucose …

Updated Date: Jun 1, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Authors: Rodriguez-Tudela JL, Gomez-Lopez A, Arendrup MC, Garcia-Effron G, Perlin DS, Lass-Flörl C, Cuenca-Estrella M
According to the product insert for Cancidas, the drug must not be diluted in solutions containing glucose as this decreases caspofungin stability. The aim of this study is to compare caspofungin MICs for a collection of yeasts by means of EUCAST EDef7.1 but using two different concentrations of glucose, 2% versus 0.2%. MICs were identical or within one twofold dilution for 93 out of 95 strains (97.9%) of strains showing that glucose …

Updated Date: Sep 11, 2008 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Cancidas (Caspofungin Acetate) drug description – FDA approved labeling for prescription drugs and medications at RxList (Source: RxList – New and Updated Drug Monographs)

(Source: Merck.com – Product News)

Cancidas, previously approved for use in adults, can now be applied also to pediatric patients aged
three months to 17 years. (Source: Drug Topics – Drug Information)

MedWorm Message: Register for MedMatcha, MedWorm’s medical advertising network, and receive $5 free advertising.

Cancidas, previously approved for use in adults, can now be applied also to pediatric patients aged
three months to 17 years. (Source: Drug Topics – Hot off the Press)

Merck & Co., Inc. announced that the U.S. Food and Drug Administration (FDA) has approved an expanded label for Cancidas®, which makes it the first and only echinocandin therapy approved in the United States for the treatment of pediatric patients aged 3 months to 17 years with indicated fungal infections. (Source: Pediatrics News From Medical News Today)